Share on StockTwits

Salix Pharmaceuticals (NASDAQ:SLXP)‘s stock had its “buy” rating restated by equities researchers at Jefferies Group in a research report issued on Tuesday, Analyst Ratings Network.com reports. They currently have a $133.00 price objective on the stock. Jefferies Group’s price objective would indicate a potential upside of 21.97% from the stock’s previous close.

Shares of Salix Pharmaceuticals (NASDAQ:SLXP) traded up 0.29% on Tuesday, hitting $109.04. 706,353 shares of the company’s stock traded hands. Salix Pharmaceuticals has a 52 week low of $51.96 and a 52 week high of $120.00. The stock’s 50-day moving average is $106.1 and its 200-day moving average is $94.18. The company has a market cap of $6.906 billion and a price-to-earnings ratio of 49.87.

Salix Pharmaceuticals (NASDAQ:SLXP) last issued its quarterly earnings data on Thursday, February 27th. The company reported $1.06 EPS for the quarter, beating the Thomson Reuters consensus estimate of $0.93 by $0.13. The company had revenue of $257.60 million for the quarter, compared to the consensus estimate of $247.29 million. During the same quarter in the prior year, the company posted $0.81 earnings per share. The company’s quarterly revenue was up 30.0% on a year-over-year basis. Analysts expect that Salix Pharmaceuticals will post $6.59 EPS for the current fiscal year.

In other Salix Pharmaceuticals news, Director Alonzo Thomas D sold 11,530 shares of Salix Pharmaceuticals stock on the open market in a transaction dated Tuesday, April 22nd. The shares were sold at an average price of $110.89, for a total transaction of $1,278,561.70. Following the sale, the director now directly owns 79,179 shares in the company, valued at approximately $8,780,159. The transaction was disclosed in a filing with the SEC, which is available at this link.

SLXP has been the subject of a number of other recent research reports. Analysts at Zacks upgraded shares of Salix Pharmaceuticals from a “neutral” rating to an “outperform” rating in a research note on Friday. They now have a $133.00 price target on the stock. Separately, analysts at Sterne Agee initiated coverage on shares of Salix Pharmaceuticals in a research note on Wednesday, April 16th. They set a “buy” rating and a $126.00 price target on the stock. Finally, analysts at National Alliance Securities initiated coverage on shares of Salix Pharmaceuticals in a research note on Tuesday, March 18th. They set a “buy” rating and a $134.62 price target on the stock. One analyst has rated the stock with a sell rating, four have issued a hold rating and eight have given a buy rating to the company. The company has a consensus rating of “Buy” and a consensus target price of $105.03.

Salix Pharmaceuticals, Ltd. is a specialty pharmaceutical company dedicated to acquiring, developing and commercializing prescription drugs and medical devices used in the treatment of a variety of gastrointestinal disorders, which are those affecting the digestive tract.

Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.